Shortly after having finished his degree in 1987, Kåre Schultz joined Novo Nordisk A/S in 1989. In January 2014, he was appointed Novo Nordisk A/S’s President and Chief Operating Officer (COO). Kåre Schultz joined Lundbeck in May 2015.
Kåre Schultz holds a Master of Science in Economics from the University of Copenhagen, Denmark.
Kåre Schultz is Chairman of the Board of Royal Unibrew A/S and a member of the Board of LEGO A/S, both in Denmark.
Following his degree in medicine and research fellow positions at Copenhagen hospitals, Anders Gersel Pedersen worked for Eli Lilly for 11 years: 10 of these as a director overseeing worldwide clinical research in oncology. In 2000 he joined Lundbeck as Vice President of International Clinical Research, he was later appointed Executive Vice President of Drug Development and in 2011 appointed responsible for all Research & Development activities at Lundbeck.
He is a member of the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology, the Danish Society of Medical Oncology and the Danish Society of Internal Medicine. Anders Gersel Pedersen also serves on the Board of Directors at Bavarian Nordic A/S and ALK-Abelló A/S and is Chairman in Genmab A/S.
After finishing his education, Anders Götzsche joined PriceWaterhouseCoopers in 1991. From 1998 he was a Sales Manager with the SAS Institute until 2001, after which he became Director of Group Accounting and Reporting in Group 4 Falck. From 2005 he held the post of Chief Financial Officer for the Berlingske Officin. He joined Lundbeck in 2007.
Anders Götzsche holds a Master of Science in Accounting from University of Southern Denmark (1991) and he became a state authorized public accountant in 1997.
Anders Götzsche is the Chairman in Rosborg Møbler A/S and serves on the Board of Directors of Veloxis Pharmaceutical A/S.